A5 Laboratories Inc.
OTC Bulletin Board : AFLB

A5 Laboratories Inc.

September 29, 2010 09:01 ET

A5 Laboratories Inc. Announces Additional CRO Customers

MONTREAL, QUEBEC--(Marketwire - Sept. 29, 2010) - A5 Laboratories Inc. (A5 Labs) (OTCBB:AFLB) announced today that its CRO division has successfully added several additional customers for its environmental assessment business unit. A5 Labs will provide these customers a variety of phase 1, 2 and 3 environmental assessment testing and reporting services including testing of industrial water, soil and atmospheric emissions. Specifically, A5 Labs will provide the following services:

  • Industrial water testing for Avior Integrated Products (supplier of lightweight structural assemblies for international aerospace industry), F.D. Jul (manufacturer of shelving systems and mobile storage units) and Bel products (manufacturer of electronic enclosures)
  • Product contamination assessment for Vulcain, a division of Honeywell, a manufacturer of environmental detection systems
  • Phase 1, 2 and 3 water and soil contamination testing for Bank of Montreal and National Bank of Canada. A5 Labs will conduct these tests for properties under financing consideration by these banks.
  • Phase 1 environmental assessment for Century 21 (real estate company) in Quebec
  • Atmospheric emissions testing and assessment for Le Plastique Balcan and Multisac packaging (leading manufacturers of flexible packaging and lamination films).

"I am very pleased with the progress of our CRO group and the environmental assessment unit. Addition of these customers will greatly increase our visibility and penetration in the environmental assessment market. We plan to build on this momentum and significantly increase our sales for the coming fiscal year." said Dr. Richard Azani, President and CEO.

More information about the Company is available at its corporate website at www.a5labs.com.

About A5 Labs:

A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.

Safe Harbor Statement:

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as "plan", "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to A5, its ability to increase sales, or its management, identify forward-looking statements. Such forward-looking statements as are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors such as the level of business and consumer spending, the amount of sales of A5's products, the competitive environment within the industry, the ability of A5 to continue to expand its operations, the level of costs incurred in connection with A5's expansion efforts, economic conditions in the industry and the financial strength of A5's customers and suppliers. A5 does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.

Contact Information